KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Nomograms for predicting survival in patients with micropapillary bladder cancer: a real-world analysis based on the surveillance, epidemiology, and end results database and external validation in a tertiary center. PMID 36782165 · BMC Urol · 2023-Feb-13 The study is a retrospective, real-world prognostic nomogram analysis for micropapillary bladder cancer. It uses time-to-event endpoints (CSS, OS) but lacks the required drug-containing intervention and is not a Phase III/IIIb or Phase II/III randomized trial of a therapeutic agent.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Colorectal cancer survivors' long-term recollections of their illness and therapy up to seven years after enrolment into a randomised controlled clinical trial. PMID 36782134 · BMC Cancer · 2023-Feb-13 This is a qualitative study on long-term survivor recollections from a prior RCT on quality of life improvement. It does not report time-to-event efficacy data (e.g., OS, PFS) from a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial. PMID 36782325 · Infect Agent Cancer · 2023-Feb-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Nomograms for predicting overall survival and cancer-specific survival in patients with head and neck non-Hodgkin lymphoma: A population-based study. PMID 36820559 · Medicine (Baltimore) · 2023-Feb-10 Study is an oncology, human, time-to-event, original research (nomogram development) with a primary analysis, but it is a population-based observational study, not a randomized controlled trial. It lacks the required randomized design, drug-containing intervention, and Phase III/IIIb or Phase II/III evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. PMID 36763878 · Br J Dermatol · 2023-Feb-10 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H B
仅广召回影子组 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Smartphone Psychotherapy Reduces Fear of Cancer Recurrence Among Breast Cancer Survivors: A Fully Decentralized Randomized Controlled Clinical Trial (J-SUPPORT 1703 Study). PMID 36322882 · J Clin Oncol · 2023-Feb-10 The study is an oncology randomized controlled trial in human breast cancer survivors, reporting original primary results. However, it is excluded because the intervention is a non-drug-only smartphone psychotherapy application, not a drug-containing intervention. Additionally, the trial phase is not specified as Phase III/IIIb or definitive Phase II/III, and the primary/secondary endpoints are psychometric scales, not time-to-event outcomes (OS, PFS, etc.) or Kaplan-Meier/HR analyses.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JSpA): study protocol for a randomized pragmatic trial. PMID 36755328 · Trials · 2023-Feb-08 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data. PMID 36367377 · Oncologist · 2023-Feb-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Preoperative combined mechanical and oral antibiotic bowel preparation for preventing complications in elective colorectal surgery. PMID 36748942 · Cochrane Database Syst Rev · 2023-Feb-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A Novel Approach to Determining Tumor Progression Using a Three-Site Pilot Clinical Trial of Spectroscopic MRI-Guided Radiation Dose Escalation in Glioblastoma. PMID 36828381 · Tomography · 2023-Feb-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The COMFORT trial: a randomised control trial comparing group-based COMpassion-FOcussed therapy and breathing pattern ReTraining with treatment as usual on the psychological functioning of patients diagnosed with cancer recurrence during COVID. PMID 36747246 · Trials · 2023-Feb-06 The record describes a protocol for a randomized trial of a psychological intervention (compassion-focused therapy and breathing retraining) for cancer recurrence. It meets oncology, human, and randomized criteria. However, it is not a drug intervention trial, does not report a Phase III/IIIb or Phase II/III study, lacks a time-to-event efficacy endpoint (primary endpoint is a distress score), and is a protocol without results. Therefore, it is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of invasive aspergillosis on risk for different causes of death in older patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome. PMID 36747127 · BMC Infect Dis · 2023-Feb-06 The report is a secondary analysis of cause-specific mortality from a randomized trial, not a primary efficacy report with a time-to-event endpoint. The underlying trial phase is not confirmed as definitive.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
One-year nutrition counselling in the context of a Mediterranean diet reduced the dietary inflammatory index in women with breast cancer: a role for the dietary glycemic index. PMID 36655860 · Food Funct · 2023-Feb-06 The record is an original RCT with oncology and human subjects, but it is excluded because it lacks a drug-containing intervention and a time-to-event efficacy endpoint, and the trial phase is not definitively Phase III or similar.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Construction of a cuproptosis-associated long non-coding RNA risk prediction model for pancreatic adenocarcinoma based on the TCGA database. PMID 36749249 · Medicine (Baltimore) · 2023-Feb-03 The record describes a bioinformatics/prognostic modeling study using public TCGA data. It is not a clinical trial with a drug intervention, does not report a randomized Phase II/III trial, and does not present a primary time-to-event efficacy endpoint for a drug. The 'Randomized' publication type tag is likely incorrect for the study design.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: protocol for a pilot fractional factorial trial. PMID 36737093 · BMJ Open · 2023-Feb-03 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Estimation of cell lineages in tumors from spatial transcriptomics data. PMID 36732531 · Nat Commun · 2023-Feb-02 The record describes a methodological/bioinformatics study developing a computational tool for analyzing spatial transcriptomics data from tumors, not a clinical trial. Although the publication type lists 'Randomized Controlled Trial', the title, abstract, and context clearly indicate it is a non-interventional, computational research article. It lacks a drug-containing intervention, a Phase III/IIIb or Phase II/III randomized trial design, and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) as required for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer. PMID 36853609 · JAMA Netw Open · 2023-Feb-01 The study is a retrospective cohort, not a randomized trial, and does not specify a Phase III/IIIb or Phase II/III designation. Therefore, it fails the core eligibility requirement of being a randomized trial with definitive phase evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Management of Marginal Zone Lymphoma: A Canadian Perspective. PMID 36826096 · Curr Oncol · 2023-Feb-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effect of Laparoscopic Proximal Gastrectomy With Double-Tract Reconstruction vs Total Gastrectomy on Hemoglobin Level and Vitamin B12 Supplementation in Upper-Third Early Gastric Cancer: A Randomized Clinical Trial. PMID 36790808 · JAMA Netw Open · 2023-Feb-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
A NEw MOdel of individualized and patient-centered follow-up for women with gynecological cancer (the NEMO study)-protocol and rationale of a randomized clinical trial. PMID 36726187 · Trials · 2023-Feb-01 The record is a protocol for a randomized clinical trial in gynecological cancer. While it meets criteria for being oncology, human, and randomized, it fails three critical inclusion criteria: 1) It does not involve a drug-containing intervention (the intervention is nurse-led follow-up), 2) It does not have a primary or secondary time-to-event efficacy endpoint (outcomes are empowerment and quality of life questionnaires), and 3) It is a protocol without reported results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Discussion: Three-Year Recurrence of Dupuytren Contracture after Needle Fasciotomy or Collagenase Injection: A Randomized Controlled Trial. PMID 36696320 · Plast Reconstr Surg · 2023-Feb-01 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021. PMID 36580315 · JAMA Oncol · 2023-Feb-01 This record is a review article analyzing the use of single-arm trials in FDA drug approvals, not an original report of a specific randomized Phase III/IIIb or Phase II/III trial with a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cost-effectiveness of Laparoscopic vs Open Gastrectomy for Gastric Cancer: An Economic Evaluation Alongside a Randomized Clinical Trial. PMID 36576822 · JAMA Surg · 2023-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial. PMID 36547975 · JAMA Oncol · 2023-Feb-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial. PMID 36529304 · Int J Cardiol · 2023-Feb-01 The trial is a randomized, placebo-controlled Phase III study (LoDoCo2) of colchicine in chronic coronary disease, which is a cardiovascular indication, not a human malignant neoplasm. Therefore, it is excluded from the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association of Primary Tumor Volume With Survival in Patients With T3 Glottic Cancer Treated With Radiotherapy: A Study of the Canadian Head & Neck Collaborative Research Initiative. PMID 36480193 · JAMA Otolaryngol Head Neck Surg · 2023-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Endoscopic balloon cryoablation plus transurethral resection for bladder cancer: A phase 2, multicenter, randomized, controlled trial. PMID 36477612 · Cancer · 2023-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of Geriatric Assessment and Management on Quality of Life, Unplanned Hospitalizations, Toxicity, and Survival for Older Adults With Cancer: The Randomized 5C Trial. PMID 36473126 · J Clin Oncol · 2023-Feb-01 While the study is a randomized, human oncology trial with a drug-containing context and reports overall survival, it fails key criteria: 1) the primary endpoint is quality of life (not a time-to-event efficacy endpoint), 2) overall survival is only a secondary outcome, 3) the intervention is geriatric management (not a drug therapy), and 4) there is no explicit evidence of Phase III or Phase II/III designation. The report is thus excluded from the KM digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. PMID 36469573 · Clin Cancer Res · 2023-Feb-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. PMID 36454580 · JAMA Oncol · 2023-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation. PMID 36451343 · Cancer · 2023-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial. PMID 36449695 · Clin Cancer Res · 2023-Feb-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis. PMID 36416812 · JAMA Oncol · 2023-Feb-01 This record is a meta-analysis examining enrollment disparities in prostate cancer clinical trials. It is not an original report of a single randomized trial with a drug intervention and a time-to-event efficacy endpoint. The analysis includes Phase 2/3 trials, but the report itself is a review/synthesis, not a primary trial result.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Surgical salvage of human papillomavirus-positive oropharyngeal cancer: Secondary analysis of a randomized controlled trial. PMID 36401615 · Cancer · 2023-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Three-Year Recurrence of Dupuytren Contracture after Needle Fasciotomy or Collagenase Injection: A Randomized Controlled Trial. PMID 36342689 · Plast Reconstr Surg · 2023-Feb-01 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. PMID 36256912 · J Clin Oncol · 2023-Feb-01 The record meets most eligibility criteria (oncology, human, randomized, drug intervention, time-to-event primary endpoint, original result). However, the trial phase is not explicitly established in the provided metadata (title, abstract, publication types, MeSH, deterministic review signals). Therefore, the overall eligibility cannot be determined as true per the instruction to set 'is_eligible' to true only when every required criterion is explicitly established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
WISER Survivor Trial: Combined Effect of Exercise and Weight Loss Interventions on Inflammation in Breast Cancer Survivors. PMID 36170550 · Med Sci Sports Exerc · 2023-Feb-01 Eligibility criteria not met: the study lacks a drug-containing intervention and a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world. PMID 36053905 · Int J Cancer · 2023-Feb-01 The study is a prospective real-world cohort study with propensity score analysis, not a randomized controlled trial. It lacks explicit evidence of being a Phase III/IIIb or Phase II/III randomized trial, which is a required criterion. Therefore, it is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic Significance of Negative Lymph Node Long Axis in Esophageal Cancer: Results From the Randomized Controlled UK MRC OE02 Trial. PMID 34520429 · Ann Surg · 2023-Feb-01 The record is an original report of a randomized trial in human oncology with a drug intervention and a time-to-event endpoint. However, it presents a subgroup/biomarker analysis rather than the primary efficacy analysis of the trial's treatment comparison. The definitive trial phase is not established in the metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Lymph Node Dissection on Survival After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: From the Results of NEOCRTEC5010, a Randomized Multicenter Study. PMID 33605586 · Ann Surg · 2023-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Designing Effective Alcohol Warnings: Consumer Reactions to Icons and Health Topics. PMID 37575887 · Am J Prev Med · 2023-Feb This is a randomized survey study on consumer reactions to alcohol warning labels, not an oncology therapeutic trial. It lacks a drug intervention, any Phase III classification, and any time-to-event efficacy endpoint (OS, PFS, etc.). The primary outcome is a Likert-scale rating of label effectiveness, not a survival or progression metric.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Possible immuno-modulatory effects of tocilizumab in patients with refractory status epilepticus. PMID 36876691 · Eur Rev Med Pharmacol Sci · 2023-Feb The record describes a randomized controlled trial evaluating tocilizumab for refractory status epilepticus, which is a neurologic condition, not an oncology malignancy. The primary outcome is based on inflammatory biomarkers (NF-κB, IL-6, etc.), not a time-to-event efficacy endpoint like overall survival or progression-free survival. Therefore, it does not meet the oncology or time-to-event criteria for the cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial. PMID 36872927 · Liver Cancer · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. PMID 36822667 · J Immunother Cancer · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer: S Pyrhönen, T Kuitunen, P Nyandoto & M Kouri. PMID 36797355 · Br J Cancer · 2023-Feb The record describes a review article that discusses a prior RCT, but the abstract does not present original trial results with a time-to-event efficacy endpoint. Therefore, it is excluded as it does not meet the required criteria for an original result report of a randomized trial with a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Development and validation of an [18F]FDG-PET/CT radiomic model for predicting progression-free survival for patients with stage II - III thoracic esophageal squamous cell carcinoma who are treated with definitive chemoradiotherapy. PMID 36794365 · Acta Oncol · 2023-Feb The study is a randomized analysis of a radiomic model for predicting PFS in esophageal cancer patients treated with definitive chemoradiotherapy, but it does not test a drug-containing intervention and does not report a trial phase (Phase III or equivalent).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Yoga and Mediational Influence of Fatigue on Walking, Physical Activity, and Quality of Life Among Cancer Survivors. PMID 36791754 · J Natl Compr Canc Netw · 2023-Feb The study is a Phase III randomized trial in human cancer survivors, but it does not meet the core eligibility criteria because it lacks a drug-containing intervention (the intervention is yoga) and does not have a time-to-event efficacy endpoint (the outcomes are symptom interference scores and quality of life).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. PMID 36725084 · J Immunother Cancer · 2023-Feb The trial is a phase 3B study with a drug intervention and reports a time-to-event efficacy outcome (OS), but the primary endpoint was safety, not a primary/key secondary time-to-event efficacy endpoint as required.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Contrast-enhanced Ultrasound Using Intradermal Microbubble Sulfur Hexafluoride for Identification of Sentinel Lymph Nodes During Breast Cancer Surgery: A Clinical Trial. PMID 36697065 · Anticancer Res · 2023-Feb Eligibility criteria not met: the study is not randomized and lacks a drug-containing intervention and a time-to-event efficacy endpoint. It is a single-arm Phase III study evaluating a diagnostic imaging technique for sentinel lymph node mapping, not a therapeutic trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial. PMID 36681089 · Lancet Oncol · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -